Aclaris says bosakitug trial failed to meet targets in atopic dermatitis
Key Facts
Aclaris Therapeutics announced on November 16, 2026, that the Phase 2 ADMIRATION trial of bosakitug, also known as ATI-045, failed to meet its primary or secondary endpoints in patients with moderate-to-severe atopic dermatitis. The primary endpoint was the percentage change from baseline in the Eczema Area and Severity Index at Week 24. In a statement accompanying a filing with the U.S. Securities and Exchange Commission, the company said the trial missed that target, putting the clinical program's result at the center of the announcement. The available evidence did not include a reliable figure for Aclaris shares' premarket move, so no specific percentage decline can be attributed to the announcement.
ADMIRATION tested the efficacy and safety of bosakitug, a monoclonal antibody targeting TSLP, in patients with moderate-to-severe atopic dermatitis. Missing the primary endpoint represents a failure on the prespecified measure for assessing changes in disease severity over the study period. The company did not report a numerical result for the primary endpoint or quantitative details for the secondary endpoints in the available information, but confirmed that both were missed. It said the drug was generally well tolerated in the trial. The statement thus distinguished the clinical efficacy result from the tolerability observation, without changing the announced failure to meet the study's endpoints.
Aclaris, by contrast, said pharmacodynamic results showed strong engagement with the TSLP target, alongside reductions in markers associated with immune activation, including Th1, Th2 and Th17. The observation describes a biological response to the drug within the targeted pathway, but came alongside the trial's failure to meet its primary and secondary clinical endpoints. The company did not provide numerical values for the size of the reductions in those markers in the filing cited here. Chief Executive Neil Walker said the company was "disappointed that the ADMIRATION trial did not overcome the historical challenges" of using a TSLP-targeting antibody alone to treat atopic dermatitis. The comment places the trial result within the challenge the company itself identified for this therapeutic approach.
The ADMIRATION result follows an earlier Phase 2a proof-of-concept trial of bosakitug conducted by Biosion in 22 patients, which was single-arm. Those were results from an earlier trial, not the ADMIRATION trial that the company said failed on November 16. In a previous filing, the company said ADMIRATION was designed for about 96 patients and that it expected topline data in the second half of 2026. That background shows the differences in design and timing between the two programs, without allowing results from the smaller trial to stand in for the latest study's result.
Aclaris said ADMIRATION's failure does not change its development priorities, which remain focused on oral kinase inhibitors and the bispecific antibody ATI-052. In a previous filing, the company said its Phase 1b trial of ATI-052 in atopic dermatitis included 14 patients, and that the prespecified analysis set comprised 9 patients who received the drug and one who received placebo. Those results remain part of the separate ATI-052 program, apart from bosakitug and the ADMIRATION trial. The company also said it had about $204.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, according to its third-quarter results filing.
The next milestone the company identified is the start of a Phase 2b trial of ATI-052 in eosinophilic esophagitis during the first quarter of 2027. Aclaris had previously indicated its intention to start the trial in early 2027, before its latest statement specified the first quarter as the target timing. It said its development focus would remain on oral kinase inhibitors and ATI-052 despite the ADMIRATION result. In a separate biotechnology development on November 16, Summit Therapeutics disclosed that the U.S. Food and Drug Administration had found its application for ivonescimab unapprovable in its current form, citing a lack of substantial evidence of effectiveness amid no statistically significant improvement in overall survival. That decision relates to ivonescimab and Summit's regulatory filing, not Aclaris's results in atopic dermatitis.